TEM: Tempus AI Company Sales Revenue

Corporate emblem and logo of Tempus AI, Inc. (TEM)

Tempus AI, Inc (TEM) minimizes risks by synthesizing AI with genetics to optimize therapy and drug development. The company's current sales levels confirm financial stability, where 1.51 expresses today's metric value. Leadership is driven by a unique clinical-genomic database that is indispensable for oncologists. The business is currently executing an expansion plan, aggressively monetizing its data library for the benefit of the pharmaceutical industry.

Tempus (TEM) Company Revenue: for the period 06/15/2024 - 11/13/2026

Analytical breakdowns for Tempus AI (TEM)

- market value and analyst target forecast:
- market capitalization information:
Summary company analysis:TEM (Tempus Labs)
Signature product of Tempus

This metric reflects the aggregate cash flow from the sale of products and services, serving as a core measure of commercial efficiency. Revenue growth confirms the demand for Tempus AI, Inc (TEM) solutions in precision medicine and the company's ability to maintain pricing power due to the uniqueness of its AI analytics. By analyzing the company's total sales, an investor can assess the pace of business expansion. The positive trend of the line indicates a scaling of market share. A steady increase in the volume of inflows confirms the high fundamental stability of the model.

Analysis of competing companies

Qiagen Corp (QGEN) - Company Gross Revenue|Company Sales IONS (Ionis Pharmaceuticals)|RGEN (repligen.com) - Company Sales Revenue|Revenue and Sales Volume RNA (Avidity Biosciences, Inc.)|Company Gross Revenue CRISPR Therapeutics Inc (CRSP)|WGS - Company Revenue|RARE (Ultragenyx Corp) - Company Sales Volume|BEAM: Revenue and Sales Volume|Company Sales sarepta.com|Company Sales TWST|TXG (10x Genomics Inc) - Company Total Sales|Revenue and Sales Volume NTLA|STOK - Company Total Revenue|Company Revenue BioLife Solutions, Inc. BLFS|WVE - Company Sales|Maze Therapeutics - Revenue and Sales Volume|SION (Sionna Therapeutics, Inc.) - Company Sales Volume|Prime Medicine Corp (PRME) - Company Revenue|Company Sales Volume TSHA|QURE (uniQure N.V.) - Revenue and Sales Volume|Revenue and Sales Volume meiragtx.com|Company Sales RGNX (REGENXBIO)|Company Total Sales SLDB|Revenue and Sales Volume OCGN (Ocugen Corp)|PacBio Corp (PACB) - Company Total Revenue|BNTC - Company Revenue|designtx.com (DSGN) - Company Sales|Rocket Pharmaceuticals, Inc. (RCKT) - Company Revenue|Company Annual Revenue FDMT (4DMT)|Company Sales LXEO|Revenue and Sales Volume Korro Bio, Inc|Company Revenue Editas Medicine, Inc. (EDIT)|Company Gross Revenue silence-therapeutics.com|ProQR Therapeutics - Company Sales|Company Sales Revenue CDXS|Sangamo - Revenue and Sales Volume|NAUT - Revenue and Sales Volume|MGX: Revenue and Sales Volume|DTIL - Company Gross Revenue|Company Sales GBIO|BOLD: Company Sales Revenue|Revenue and Sales Volume XCUR|Company Gross Revenue imunon.com|Company Revenue Phio Pharmaceuticals Corp. PHIO|MBIO: Company Sales Volume|TransCode - Revenue and Sales Volume|Bionano Genomics, Inc. (BNGO) - Company Sales|APDN (Applied DNA) - Company Sales|BLUE: Company Total Sales|IPA (ImmunoPrecise Antibodies Ltd) - Revenue and Sales Volume|Company Total Revenue omegatherapeutics.com OMGA|Company Revenue Singular Genomics (OMIC)|Company Sales Regulus Therapeutics, Inc. RGLS|Revenue and Sales Volume SYRS (Syros)|TBIO: Company Sales Volume|TCON - Company Revenue|UBX (unitybiotechnology.com) - Company Sales Volume